Markets

Summit Therapeutics Reports Updated Overall Survival Trend In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved Survival Trend; PDUFA Goal Action Date November 14

Jul 22, 2026 · 06:36 AM ET· updated 1h ago

Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III StudySummit Therapeutics Inc. (NASDAQ:SMMT) today announced results of an updated overall survival (OS) analysis from the

Why It Matters

Summit Therapeutics found that their new cancer medicine helped patients live longer in a big test—with better results matching what they saw in different parts of the world. The government will decide by November 14 if they can sell it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SMMT15.20

+0.56 (+3.86%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.